Literature DB >> 16216364

Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients.

Yongjin Wang1, Bernard Cummings, Pamela Catton, Laura Dawson, John Kim, Jolie Ringash, Rebecca Wong, Qi-Long Yi, James Brierley.   

Abstract

BACKGROUND AND
PURPOSE: To assess local control, survival and toxicity following primary radical external beam radiotherapy of rectal adenocarcinoma treated between 1978 and 1997, and to compare practices and outcomes between the two decades of study. PATIENTS AND METHODS: A retrospective review of 271 patients who underwent primary radical external beam radiotherapy, without prior or concurrent chemotherapy, was conducted. All patients received radiation doses of at least 40 Gy. Most patients (82%) were followed until death.
RESULTS: Tumor fixation was the only significant prognostic factor for complete response by multivariate analysis. Complete response rates for mobile, partially fixed and fixed tumors were 49, 22 and 9%, respectively. For patients with mobile, partially fixed and fixed tumors, overall 5 year survival was 48, 26 and 6%, respectively, and cancer specific 5 year survival was 59, 33 and 9%, respectively. On multivariate analysis, tumor fixation and CEA higher than 8.7 microg/L at presentation were associated with significantly shortened survival. Outcomes did not change significantly during the two decades of the study. RTOG grade 3 or higher acute (1.8%) and late (1.5%) toxicity occurred only in the first decade of study.
CONCLUSIONS: Radical external beam radiotherapy is a reasonable treatment option for rectal carcinoma for patients who are not surgical candidates or refuse surgery. However in patients with fixed tumors in this study, the outcome is poor and treatment should be considered palliative. Severe radiation toxicity is infrequent with current schedules and techniques of radiotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 16216364     DOI: 10.1016/j.radonc.2005.09.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.

Authors:  Julio Garcia-Aguilar; David D Smith; Karin Avila; Emily K Bergsland; Peiguo Chu; Richard M Krieg
Journal:  Ann Surg       Date:  2011-07       Impact factor: 12.969

Review 2.  Interval to surgery after neoadjuvant treatment for colorectal cancer.

Authors:  Nir Wasserberg
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy.

Authors:  José Luis López Guerra; Antonio José Lozano; Joan Pera; Cristina Gutiérrez; María Cambray; Ferran Ferrer; Ferran Guedea
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

4.  Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases.

Authors:  Maria Chiara Tronconi; Carlo Carnaghi; Mario Bignardi; Roberto Doci; Lorenza Rimassa; Mariagrazia Di Rocco; Marta Scorsetti; Armando Santoro
Journal:  Int J Colorectal Dis       Date:  2010-06-15       Impact factor: 2.571

Review 5.  Locally advanced rectal cancer: a comparison of management strategies.

Authors:  Robert Glynne-Jones; Miranda Kronfli
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

6.  Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer: A Multicenter Comparative Cross-Sectional Study with Rectal Preservation as Supported by Surgeon.

Authors:  Kwang-Seop Song; Sung Chan Park; Dae Kyung Sohn; Jae Hwan Oh; Min Jung Kim; Ji Won Park; Seung-Bum Ryoo; Seung-Yong Jeong; Kyu Joo Park; Heung-Kwon Oh; Duck-Woo Kim; Sung-Bum Kang
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

7.  Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach.

Authors:  Maximilian Fleischmann; Markus Diefenhardt; Martin Trommel; Christian Scherf; Ulla Ramm; Georgios Chatzikonstantinou; Emmanouil Fokas; Claus Rödel; Nikolaos Tselis
Journal:  Strahlenther Onkol       Date:  2022-04-20       Impact factor: 4.033

8.  MITHRA - multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study.

Authors:  Luca Tagliaferri; Stefania Manfrida; Brunella Barbaro; Maria Maddalena Colangione; Valeria Masiello; Gian Carlo Mattiucci; Elisa Placidi; Rosa Autorino; Maria Antonietta Gambacorta; Silvia Chiesa; Giovanna Mantini; György Kovács; Vincenzo Valentini
Journal:  J Contemp Brachytherapy       Date:  2015-10-19

9.  Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).

Authors:  Evaghelos Xynos; Paris Tekkis; Nikolaos Gouvas; Louiza Vini; Evangelia Chrysou; Maria Tzardi; Vassilis Vassiliou; Ioannis Boukovinas; Christos Agalianos; Nikolaos Androulakis; Athanasios Athanasiadis; Christos Christodoulou; Christos Dervenis; Christos Emmanouilidis; Panagiotis Georgiou; Ourania Katopodi; Panteleimon Kountourakis; Thomas Makatsoris; Pavlos Papakostas; Demetris Papamichael; George Pechlivanides; Georgios Pentheroudakis; Ioannis Pilpilidis; Joseph Sgouros; Charina Triantopoulou; Spyridon Xynogalos; Niki Karachaliou; Nikolaos Ziras; Odysseas Zoras; John Souglakos
Journal:  Ann Gastroenterol       Date:  2016 Apr-Jun

Review 10.  Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

Authors:  Jun Li; Lunjin Li; Lin Yang; Jiatian Yuan; Bo Lv; Yanan Yao; Shasha Xing
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.